2018. Identification of Potential Therapeutic Targets in Prostate Cancer through a Cross-Species Approach. Jurmeister S*, Ramos-Montoya A*, Sandi C, Pértega-Gomes N, et al. EMBO Mol Med. PMID: 29437778
2017. MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pértega-Gomes N, et al. Cancer Epidemiol Biomarkers. PMID: 29141848
2016. Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer. Pinto F, Pértega-Gomes N, et al. Oncotarget. PMID: 27049720
2015. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, et al. J Natl Cancer Inst. PMID:26657335
2015. Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer. Pértega-Gomes N, et al. Oncotarget. PMID:26035357
2015. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. Pértega-Gomes N, et al. J Pathol. PMID:25875424
2015. Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer. Valença I*, Pértega-Gomes N*,(*First authorship is shared). J Cell Mol Med PMID: 25639644
2014. Lactate transporters in the context of prostate cancer metabolism: what do we know? Pértega-Gomes N et al. Int J Mol Sci. PMID: 25314297
2014. T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Pinto F, Pértega-Gomes N, et al. Clin Cancer Res. PMID:25009296
2014. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. Pértega-Gomes N, et al. BMC Cancer PMID: 24886074
2014. Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. Zecchini V, Basetti M, Russell R, Pértega-Gomes N, et al. EMBO J. PMID: 24837709
2013. Pértega-Gomes N, et al. Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. The Prostate PMID: 23192371
2011. Pértega-Gomes N, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer PMID: 21787388